Navigation Links
NIH launches trial of investigational genital herpes vaccine
Date:11/8/2013

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

Genital herpes is one of the most common sexually transmitted infections in the United States. Most genital herpes cases are caused by infection with herpes simplex virus type 2 (HSV-2); however, herpes simplex virus type 1 (HSV-1) can also cause genital herpes. An estimated 776,000 people in the United States are infected with HSV-2 or HSV-1 each year. There is no vaccine to prevent genital herpes.

"Although genital herpes is treatable, it is a lifelong infection that can exact a substantial psychological and physical toll on infected individuals and places them at higher risk of acquiring HIV," said NIAID Director Anthony S. Fauci, M.D. "Furthermore, mothers with active genital herpes infection at time of delivery can transmit the virus to their newborns, which can lead to severe illness and death."

"A protective vaccine would help to reduce significantly the spread of this all-too- common sexually transmitted infection," Fauci added.

Led by principal investigator Lesia K. Dropulic, M.D., of NIAID's Laboratory of Infectious Diseases, the trial will test an investigational HSV-2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response. The investigational vaccine manufactured by Sanofi Pasteur was developed by David Knipe, Ph.D., professor of microbiology and immunobiology at Harvard Medical School, Boston.

Preclinical testing of the candidate vaccine involved a 10-year collaborative effort between Dr. Knipe and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases. The experimental product is a replication-defective
'/>"/>

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Hope For The Warriors® is ... to be hosted in Boston, Massachusetts on Sunday, November ... This signature event honors the courage of our wounded ... fallen. Proceeds from the evening will benefit Hope For ... sense of self, restoring the family unit, and restoring ...
(Date:9/23/2014)... Ithaca, New York (PRWEB) September 23, 2014 ... vulvodynia, interstitial cystitis, pudendal neuralgia, and other chronic pelvic or ... to lasting relief. , According to the Gallup poll, 1 ... suffer from chronic pelvic pain. Many of those women ... with their healthcare providers. The type of pain varies ...
(Date:9/23/2014)... 2014 People across Minnesota acknowledge that ... choices, but barriers are more prominent in the state’s ... Center for Prevention at Blue Cross and Blue Shield ... to healthy, affordable food and a lack of places ... About 60 percent of rural Minnesotans who responded to ...
(Date:9/23/2014)... 23, 2014). Researchers from the University of ... Krischek, investigated gene expression in normal vestibular nerves ... made: 1) there is negligible difference between VSs ... neurofibromatosis Type 2 (NF2), a genetic disorder; and ... tumors may be an excellent therapeutic target. Detailed ...
(Date:9/23/2014)... "Bee Towers” was featured on NewsWatch as part of its ... gadgets and services available to consumers. Mallory Sofastaii, a host ... and shared with viewers how it can hold tablets ... in the United States continue to climb. According to ... , For consumers who own a tablet but want ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:Mind Body Expert Launches Pelvic Pain Relief Program 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 2Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 3Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 4Health News:Minnesota Health Poll: One State, Different Challenges, Unique Solutions 5Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:“Bee Towers”, a Floor Standing Tablet Holder by XAR Motion, was Featured on NewsWatch, a National Television Show, This Month 2
... EUR10.8 Million in ... ... (Nasdaq: CHDX ), an independent American provider of international,healthcare services ... that it has signed two contracts for the,supply of EUR10.8 million ...
... Because of the demographic changes, there will be a ... in 2004, the medical costs for the care of ... In their original article in the current edition of ... 105[26]: 467󈞵), the neurologist Tobias Neumann-Haefelin of the Johann ...
... in #1 respiratory hospital ranking, DENVER, July ... traditional boundaries of respiratory medicine into,exciting new areas ... Center will become National Jewish Health, effective immediately., ... put, this isn,t just about a name change. ...
... series of online NHS Health Guides,for people with long-term ... NHS Choices http://www.nhs.uk , These online guides ... diagnosis, and through to how to live and self ... be rolling out more,guides from the 60 most common ...
... BROOK, Ill. C JULY 11, 2008 -- A study ... of Radiology,s (ACR) CT colonography guidelines recommending that polyps ≤ ... applying them to an endoscopic database that collected information about ... also recommend that patients with one or two polyps 6 ...
... Placing 15 of its 16 Ranked Specialties Ahead of All ... Clinic Specialties Rated Among Nation,s Top Ten, ... Clinic,s cardiac care has been ranked No. 1 in the nation,according ... The survey recognizes Cleveland Clinic as one of the nation,s ...
Cached Medicine News:Health News:Chindex International, Inc. Announces CDC Contract Signing 2Health News:Chindex International, Inc. Announces CDC Contract Signing 3Health News:Chindex International, Inc. Announces CDC Contract Signing 4Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 2Health News:Bold Evolution Transforms National Jewish Medical and Research Center to National Jewish Health 3Health News:Online NHS Health Guides for Long-Term Conditions Released on NHS Choices 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 2Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 3
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... May 26, 2011 Rigel Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of 16,300,000 ... of $8.00 per share to the public. The gross ... be approximately $130,400,000, before deducting underwriting discounts and commissions, ...
... Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) ... amount of senior unsecured notes. The notes will be unsecured, ... certain of the Company,s subsidiaries.   Endo intends ... cash on hand and borrowings under its new credit facility, ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes 2
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: